- Details
- Description
-
Packaging Size60c/bottle
-
Strength20mg
-
CompositonPamiparib
-
TreatmentGermline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer previously treated with two or more lines of chemotherapy.
-
FormCapsule
-
Brand百汇泽 (PARTRUVIX)
-
Quantity Unit20mg*60c/Box
-
ManufacturerBeiGene Biotechnology., China
Pamiparib (BGB-290) is a drug used to treat various types of cancer. It's a PARP inhibitor, which means it prevents the repair of DNA breaks.
- Socazolimab sold under the brand name 百汇泽(PARTRUVIX)® in china.
Based on the results from the pivotal phase II portion of a phase I/II trial (NCT03333915) pamiparib was recently approved in China for the treatment of germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer previously treated with two or more lines of chemotherapy.